CES 2022: Ultreon 1.0 Software Revolutionizes Blood Clot Imaging

To better equip doctors with critical information related to blood clots in patients, Abbott created the Ultreon 1.0 Software, the first of its kind.

The Ultreon 1.0 Software gives doctors enhanced views of blood flow and blockages with Optical coherence tomograph imaging (OCT) and AI. Ultreon detects the severity of calcium blockages and measures the vessel diameter to help the physicians make more precise decisions during coronary stenting procedures.

Ultreon can give physiological assessments of coronary blood flow and severe blockages like Resting Full-Cycle Ratio (RFR) and Fractional Flow Reserve (FFR). The software helps to detect and quantify the characteristics of blood vessels, allowing physicians to develop better insight for patient treatment.

Unlike pre-existing technologies, which use X-rays to examine the blood vessels, Ultreon uses near-infrared light for a more precise image of the blood vessels in question. The software also allows cardiologists to see inside the hard during the percutaneous coronary intervention (PCI).

AI software allows for step-by-step guidance to aid doctors in decision-making. Ultreon auto-detects and highlights the calcification arc and maximum thickness and displays real-time calcification angle and max thickness throughout the pullback, and with the co-registration view highlights calcification overlays on the blood vessel.

The AI also automatically detects the external elastic lamina (EEL) and lumen to help with finding landing zones for exact stent placement. This includes providing vessel diameter measurements, autodetects and provides measurements of the lumen and detectable EEL, and helping users identify stent length. The software also identifies if a stent is not in the proper place.

Abbott’s software is also integrated with its Dragonfly OpStar imaging catheter, which allows the physician to explore even more complex anatomical areas. The software also provides insights on morphology, vessel sizing, stent placement, and post-stent optimization.

Technology is the key to the improvement of diagnosing and treatment options in the future. Data shows that physicians altered their strategies for treating blood clots with guidance provided by OCT 88% of the time.

Abbott is a medical device and healthcare company headquartered in Chicago.